Tracking cancer drugs in living cells by thermal profiling of the proteome

@article{Savitski2014TrackingCD,
  title={Tracking cancer drugs in living cells by thermal profiling of the proteome},
  author={Mikhail M. Savitski and Friedrich B M Reinhard and Holger Franken and Thilo Werner and Maria F{\"a}lth Savitski and Dirk Eberhard and Daniel Martinez Molina and Rozbeh Jafari and Rebecca Bakszt Dovega and Susan Klaeger and Bernhard Kuster and P{\"a}r Nordlund and Marcus Bantscheff and Gerard Drewes},
  journal={Science},
  year={2014},
  volume={346}
}
INTRODUCTION Understanding drug mechanism poses the daunting challenge of determining the affinity of the drug for all potential targets. Drug target engagement can be assessed by means of a cellular thermal shift assay (CETSA) based on ligand-induced changes in protein thermal stability. We combined the CETSA method with quantitative mass spectrometry to study the effect of drugs on the thermal profile of a cellular proteome comprising more than 7000 proteins. The approach enabled the… Expand
Thermal proteome profiling for unbiased identification of direct and indirect drug targets using multiplexed quantitative mass spectrometry
TLDR
The key to this approach is the use of isobaric tandem mass tag 10-plex (TMT10) reagents to label digested protein samples corresponding to each temperature point in the melting curve so that the samples can be analyzed by multiplexed quantitative mass spectrometry. Expand
An isothermal shift assay for proteome scale drug-target identification
TLDR
The isothermal shift assay (iTSA) is presented, a mass spectrometry method for proteome-wide identification of drug targets within lysates or living cells, with improved throughput over existing methods. Expand
Identifying drug targets in tissues and whole blood with thermal-shift profiling
TLDR
Tissue thermal proteome profiling (tissue-TPP), which measures binding of small-molecule drugs to proteins in tissue samples from drug-treated animals by detecting changes in protein thermal stability using quantitative mass spectrometry, is introduced. Expand
Thermal proteome profiling: unbiased assessment of protein state through heat-induced stability changes
TLDR
Thermal proteome profiling (TPP) allows for an unbiased search of drug targets and can be applied in living cells without requiring compound labeling, and provides a novel approach to gather complementary information on protein stability not present in expression datasets. Expand
A New Drug Discovery Approach Based on Thermal Proteome Profiling to Develop More Effective Drugs
: The search for disease-related targets and studying drug-protein and protein-protein interactions are central issues that would accelerate the clinical approval of a drug. Also, by developing anExpand
Cell surface thermal proteome profiling tracks perturbations and drug targets on the plasma membrane
TLDR
This work introduces cell surface thermal proteome profiling for the comprehensive characterization of ligand-induced changes in protein abundances and thermal stabilities at the plasma membrane. Expand
Cellular thermal shift assay for the identification of drug–target interactions in the Plasmodium falciparum proteome
TLDR
The authors demonstrate two variants of the cellular thermal shift assay (CETSA) protocol—the melt curve and the isothermal dose–response—for use on intact cell or lysate P. falciparum samples for identification of antimalarial drug targets. Expand
A mass spectrometry-based proteome map of drug action in lung cancer cell lines
TLDR
A robust mass spectrometry workflow was developed for rapid drug perturbation profiling in multiple cell lines, enabling improved mechanistic deconvolution of single compounds and revealing novel mechanisms of action. Expand
Proteome thermal stability reflects organ physiology and identifies drug-target engagement in vivo
TLDR
This study generates the first proteome-wide map of protein thermal stability in tissue and provides tools that will be of great impact for translational research. Expand
A computational method for detection of ligand-binding proteins from dose range thermal proteome profiles
TLDR
This work presents a method based on statistical hypothesis testing on curves, which provides control of the false discovery rate and applies it to several datasets probing epigenetic drugs and a metabolite, to detect off-target drug engagement. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 48 REFERENCES
Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
TLDR
This cellular thermal shift assay (CETSA) is based on the biophysical principle of ligand-induced thermal stabilization of target proteins and validated drug binding for a set of important clinical targets and monitored processes of drug transport and activation, off-target effects and drug resistance in cancer cell lines, as well as drug distribution in tissues. Expand
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors
TLDR
Quantitative profiling of the drugs Imatinib, dasatinib and bosutinib in K562 cells confirms known targets including ABL and SRC family kinases and identifies the receptor tyrosine kinase DDR1 and the oxidoreductase NQO2 as novel targets of imatinib. Expand
Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination
TLDR
Two screening platforms are implemented, based on either fluorimetry or static light scattering, to measure the increase in protein thermal stability upon binding of a ligand without the need to monitor enzyme activity, and a small molecule was identified that stabilized the proteins and promoted structure determination. Expand
Direct identification of ligand-receptor interactions on living cells and tissues
TLDR
TRICEPS, a chemoproteomic reagent with three moieties—one that binds ligands containing an amino group, a second that binds glycosylated receptors on living cells and a biotin tag for purifying the receptor peptides for identification by quantitative mass spectrometry is described. Expand
Mass-spectrometry-based draft of the human proteome
TLDR
A mass-spectrometry-based draft of the human proteome and a public, high-performance, in-memory database for real-time analysis of terabytes of big data, called ProteomicsDB are presented, which enables navigation of proteomes, provides biological insight and fosters the development of proteomic technology. Expand
Chemoproteomics-based kinome profiling and target deconvolution of clinical multi-kinase inhibitors in primary chronic lymphocytic leukemia cells
TLDR
A critical role of p-TEFb inhibitors in CLL that supports their future clinical development is supported and a panel of clinical multi-kinase inhibitors for their ability to induce apoptosis in primary CLL cells is profiling. Expand
Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML.
Occurrence of the BCR-ABL(T315I) gatekeeper mutation is among the most pressing challenges in the therapy of chronic myeloid leukemia (CML). Several BCR-ABL inhibitors have multiple targets andExpand
Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer
TLDR
The inhibitor-induced RTK profile suggested a kinase inhibitor combination therapy that produced GEMM tumor apoptosis and regression where single agents were ineffective, allowing rational design of combination therapies for cancer. Expand
Affinity profiling of the cellular kinome for the nucleotide cofactors ATP, ADP, and GTP.
TLDR
An extensive and consistent data set of kinase-nucleotide affinities, determined for native enzymes under defined experimental conditions, will represent a useful resource for kinase drug discovery. Expand
Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes
TLDR
This work revealed the selectivity with which 16 HDAC inhibitors target multiple HDAC complexes scaffolded by ELM-SANT domain subunits, including a novel mitotic deacetylase complex (MiDAC) and identified several non-HDAC targets for hydroxamate inhibitors. Expand
...
1
2
3
4
5
...